Samsung Biologics Offers $1.8 Billion for PolyPeptide to Expand Into GLP-1 Peptide Drugs
Updated
Updated · CNBC · Jul 20
Samsung Biologics Offers $1.8 Billion for PolyPeptide to Expand Into GLP-1 Peptide Drugs
3 articles · Updated · CNBC · Jul 20
Summary
Samsung Biologics launched an all-cash 1.46 billion Swiss franc ($1.8 billion) tender offer for PolyPeptide, valuing the Swiss drug-ingredient maker at 44.31 francs a share and targeting closing by year-end.
The deal would push Samsung beyond antibody drugs and antibody-drug conjugates into peptide therapeutics, where demand has surged with GLP-1 obesity and diabetes treatments.
PolyPeptide's board backed the bid, calling it an attractive cash offer, while Samsung said the acquisition would be the largest biopharma M&A deal in South Korean history.
PolyPeptide brings a network spanning Sweden, Belgium, France, the U.S. and India, plus experience developing and producing more than 1,000 therapeutic peptides.
Samsung's shares slipped 1.3% early Monday as investors weighed the cost against the company's push to broaden its global manufacturing and development footprint.
Samsung Biologics has announced its plan to acquire PolyPeptide Group for about $1.8 billion, marking a major step to enter the peptide market and expand beyond traditional biologics manufacturing. This move allows Samsung Biologics to broaden its capabilities and service offerings, diversify its portfolio, and enhance its competitive edge in the evolving biopharmaceutical industry. The acquisition comes as the regulatory landscape for peptide-based therapeutics is shifting, creating both opportunities and challenges. By integrating PolyPeptide’s expertise, Samsung Biologics aims to better serve a wider range of client needs and strengthen its position in the global pharmaceutical market.